ClinicalTrials.gg
CompletedNCT01285401SOLARUpdated Nov 28, 2016Results posted

Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® Treatment

A Phase 2 interventional study of VigantOL oil plus interferon beta-1a (Rebif) and Placebo plus interferon beta-1a (Rebif) in Relapsing-Remitting Multiple Sclerosis, sponsored by Merck KGaA, Darmstadt, Germany. Completed at 38 sites in 12 countries. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2016-11-28.

Sponsored by Merck KGaA, Darmstadt, Germany · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
260
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 21 studies testing Interferon beta-1a in Multiple Sclerosis, Relapsing-Remitting — none open to participants now, none under way, none of them phase 3. Interferon beta-1a · Multiple Sclerosis, Relapsing-Remitting.

Enrollment
7th of 21
260 · median 80
Started
2011
the only one that year
Phase 2
3 of 21
none open now
Registered
16th of 21
by date
Lead sponsor
5 of 21
Merck KGaA, Darmstadt, Germany

Among the 21 studies testing Interferon beta-1a in Multiple Sclerosis, Relapsing-Remitting, this one is the 7th largest by enrollment, is the only one that started in 2011, is one of 3 in phase 2, and was the 16th registered.

Multiple Sclerosis, Relapsing-Remitting

618 studies on the registry are indexed under Multiple Sclerosis, Relapsing-Remitting; 83 are open to participants now.

Browse Multiple Sclerosis, Relapsing-Remitting studies →

Open to participants now

None of the 21 studies testing Interferon beta-1a in Multiple Sclerosis, Relapsing-Remitting is open now. The open studies under Multiple Sclerosis, Relapsing-Remitting, anywhere →

About Interferon beta-1a

Interferon beta-1a: first FDA approval 1996 (AVONEX), first EMA approval 1997. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 60 Multiple Sclerosis, Relapsing-Remitting studies recruiting now, 11 (18%) set no upper age limit and 43 (72%) stop at 75 or younger; 2 take children under 18; 11 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 21 studies testing Interferon beta-1a in Multiple Sclerosis, Relapsing-Remitting as a file.
02

Study summary

The drug being tested is called VigantOL® oil - a very effective form of Vitamin D hormone supplement (cholecalciferol). Low levels of Vitamin D have been described to be associated with a higher risk of developing Multiple Sclerosis (MS), and it is known that up to 90% of patients with Multiple Sclerosis have Vitamin D deficiency.

Rebif® is known to be an effective treatment for slowing down the progression of MS. The purpose of this research trial is to evaluate if VigantOL® oil on top of Rebif® has any benefit on the progression of MS compared to Rebif® and placebo.

Disease activity will be assessed by clinical examination and Magnetic Resonance Imaging (MRI). The planned study treatment duration for each study participant is 48 weeks, and the study consists of a total of 8 visits. Study participants who are already passed Week 48 at the time of approval of Protocol Amendment 5 will have a study duration of 96 weeks and a total of 12 visits.

During the study, the participant will undergo physical examination, neurological assessments, safety assessments, blood tests and urinalysis (including pregnancy tests).

03

Conditions studied

  • Relapsing-Remitting Multiple Sclerosis

Keywords

  • Multiple Sclerosis
  • Rebif
  • VigantOL® oil
  • Vitamin D
  • Add-on treatment
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of a relapsing-remitting form of MS
  • Brain and/or spinal MRI with findings typical of MS
  • A first clinical event prior to Screening.
  • Disease activity
  • Expanded Disability Status Scale (EDSS) score of less than, or equal to 4.0 at Screening.
  • Currently treated with interferon-beta-1a 44mg (tiw) sc
  • Willingness and ability to comply with the protocol
  • Written

Exclusion criteria

Exclusion Criteria:

  • Pregnancy and lactation period
  • Any disease other than MS that could better explain signs and symptoms.
  • Complete transverse myelitis or bilateral optic neuritis.
  • Currently receiving or use at any time of monoclonal antibodies, mitoxantrone, cytotoxic or therapy (excluding systemic and adrenocorticotrophic hormone [ACTH]), B cell modulating therapies (e.g. RituxiMab or BelimuMab), total lymphoid irradiation or bone marrow transplantation.
  • Use of any cytokine other than interferon or anti-cytokine therapy, intravenous immunoglobulin, plasmapheresis, or any drug or experimental procedure
  • Use of oral or systemic corticosteroids or ACTH
  • Have abnormalities of Vitamin D related hormonal system other than low dietary intake or decreased sun exposure, i.e. primary hyperparathyroidism or granulomatous disorders.
  • Have an urine calcium/creatinine (mmol/mmol) ratio greater than 1.0 or hypercalcaemia
  • Are taking medications that influence Vitamin D metabolism other than corticosteroids, e.g., phenytoin, barbiturates, thiazide diuretics and cardiac glycosides.
  • Are taking more than 1000 IU (25 µg) of Vitamin D supplement daily.
  • Have conditions with increased susceptibility to hypercalcaemia, e.g., known arrhythmia or heart disease, treatment with Digitalis, or Hydrochlorothiazide and those who suffer from nephrolithiasis.
  • Have inadequate liver function
  • Moderate to severe renal impairment
  • Inadequate bone marrow reserve
  • History or presence of serious or acute heart disease such as uncontrolled cardiac dysrhythmia or arrhythmia, uncontrolled angina pectoris, cardiomyopathy, or uncontrolled congestive heart failure ( class 3 or 4).
  • History or presence of severe depression, history of suicide attempt, or current suicidal ideation.
  • Epilepsy or seizures not adequately controlled by treatment.
  • Current or past alcohol or drug abuse.
  • Any major medical or psychiatric illness (such as psychosis, bipolar disorder) that in the opinion of the Investigator could create undue risk to the subject or could affect adherence with the trial protocol.
  • Known to treatment with vitamin D
  • Known to interferon or its (s)
  • Known hypersensitivity to gadolinium.
  • Any other condition that would prevent the subject from undergoing an MRI scan.
  • Signs and symptoms suggestive of transmissible spongiform encephalopathy, or family members who suffer(ed) from such.
  • Positive , , or (HBsAg and HBc antibody) serology (test performed at screening).
  • Legal incapacity or limited legal capacity.
  • Another current disease, except diabetes.
  • Have experienced a relapse within 30 days.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
260 participants (actual)

Study arms

  • Experimental
    VigantOL® oil

    VigantOL oil plus Rebif in subjects with 25-hydroxy-vitamin D plasma levels below 150 nmol/L

    Drug: VigantOL oil plus interferon beta-1a (Rebif)

  • Placebo comparator
    Placebo

    Placebo daily plus Rebif in subjects with 25-hydroxy-vitamin D plasma levels below 150 nmol/L

    Drug: Placebo plus interferon beta-1a (Rebif)

  • Experimental
    Rebif

    Rebif alone in subjects with 25-hydroxy-vitamin D plasma levels equal or higher than 150 nmol/L

    Biological: Interferon beta-1a (Rebif®) alone

Interventions

  • DrugVigantOL oil plus interferon beta-1a (Rebif)

    Drug page: Interferon beta-1a

    VigantOL oil 6,670 International Units per day (IU/d) (167 microgram per day \[mcg/day\]), was administered orally for 4 weeks followed by 14,007 IU/d (350 mcg/d) administered orally for 44 weeks on top of Rebif 44mcg three times per week (tiw) administered subcutaneously.

  • DrugPlacebo plus interferon beta-1a (Rebif)

    Matching placebo daily, orally administered matched placebo for 48 weeks on top of Rebif 44 mcg tiw.

  • Rebif® 44 mcg tiw, sub-cutaneously alone.

06

What researchers measure

Primary outcomes

  1. Percentage of Subjects With Disease Activity Free Status up to Week 48

    Disease activity free status was defined as absence of any of the clinical and imaging parameters related to the assessment of disease activity; no relapses, no expanded disability status scale (EDSS) progression and no new gadolinium (Gd)-enhancing or relaxation time 2 (T2) magnetic resonance imaging (MRI) lesions.

    Time frame: Up to Week 48

Secondary outcomes

  1. Percentage of Relapse-free Subjects at Week 48

    A relapse was defined as the development of new or the exacerbation of existing neurological symptoms or signs, in the absence of fever, lasting for 24 hours and with a previous period for more than 30 days with a stable or an improving condition.

    Time frame: Week 48

  2. Percentage of Subjects Free From Any Expanded Disability Status Scale (EDSS) Progression at Week 48

    EDSS assesses disability in 8 functional systems. An overall score ranging from 0 (normal) to 10 (death due to MS) was calculated. A confirmed EDSS progression was defined EDSS greater than or equal to 1.0 point confirmed during a visit performed 6 months later. An EDSS progression was defined as an increase of the EDSS score of at least 1.0 point compared to baseline (SD1) for subjects with a baseline EDSS ≤ 4.0. For subjects with an EDSS score of 0 at baseline (SD1), EDSS progression was defined as an increase of at least 1.5 points. A confirmed EDSS progression was defined as an EDSS progression confirmed after 24 weeks.

    Time frame: Week 48

  3. Number od Subjects With Confirmed EDSS Progression

    EDSS assesses disability in 8 functional systems. An overall score ranging from 0 (normal) to 10 (death due to MS) was calculated. A confirmed EDSS progression was defined EDSS greater than or equal to 1.0 point confirmed during a visit performed 6 months later. An EDSS progression was defined as an increase of the EDSS score of at least 1.0 point compared to baseline (SD1) for subjects with a baseline EDSS ≤ 4.0. For subjects with an EDSS score of 0 at baseline (SD1), EDSS progression was defined as an increase of at least 1.5 points. A confirmed EDSS progression was defined as an EDSS progression confirmed after 24 weeks.

    Time frame: Baseline upto 48 Weeks

  4. Cumulative Number of Relaxation Time 1 (T1) Gadolinium Enhancing Lesions at Week 48

    Time frame: 48 Weeks

  5. Mean Number of Combined Unique Active (CUA) Lesions Per Subject Per Scan at Week 48

    CUA lesions was defined as new T1 (Gd enhancing) lesions, new Relaxation time 2 (T2) lesions, or enlarging T2 lesions.

    Time frame: 48 Weeks

  6. Cumulative Number of New Combined Unique Active (CUA) Lesions at Week 48

    CUA lesions was defined as new T1 (Gd enhancing) lesions, new T2 lesions, or enlarging T2 lesions.

    Time frame: 48 Weeks

  7. Mean Change From Baseline in the Total Volume of T2 Lesions at Week 48 (T2 Burden of Disease)

    Time frame: Baseline, 48 Weeks

  8. Percentage of Subjects Free From T1 Gadolinium Enhancing Lesions at Week 48

    Time frame: 48 Weeks

  9. Percentage of Subjects Free From New T1 Hypointense Lesions (Black Holes) at Week 48

    Time frame: 48 Weeks

  10. Percentage of New T1 Hypointense Lesions (Black Holes) at Week 48 Within the Subgroup of New or Enlarging Non-enhancing T2 Lesions

    Time frame: 48 Weeks

  11. Number of Subjects With Relapse

    Relapse was defined as neurological abnormality, either newly appearing or re-appearing, with abnormality specified by both as neurological abnormality separated by at least 30 days from onset of a preceding MS attack and Neurological abnormality lasting for at least 24 hours, absence of fever or known infection greater than 37.5 degree centigrade /99.5 degree fahrenheit , objective neurological impairment, correlating with the subject's reported symptoms, defined as either increase in at least one of the functional systems of the EDSS or increase of the total EDSS score and occurrence of paraesthesia, fatigue, mental symptoms, and/or vegetative symptoms without any additional symptom will not be classified as an MS attack.

    Time frame: Baseline upto 48 weeks

  12. Annualized Relapse Rate at Week 48

    Relapse was defined as neurological abnormality, either newly appearing or re-appearing, with abnormality specified by both as neurological abnormality separated by at least 30 days from onset of a preceding MS attack and Neurological abnormality lasting for at least 24 hours, absence of fever or known infection greater than 37.5 degree centigrade /99.5 degree fahrenheit , objective neurological impairment, correlating with the subject's reported symptoms, defined as either increase in at least one of the functional systems of the EDSS or increase of the total EDSS score and occurrence of paraesthesia, fatigue, mental symptoms, and/or vegetative symptoms without any additional symptom will not be classified as an MS attack.

    Time frame: 48 weeks

  13. Total Number of Reported Relapses at All Time Points up to 48 Weeks

    Relapse was defined as neurological abnormality, either newly appearing or re-appearing, with abnormality specified by both as neurological abnormality separated by at least 30 days from onset of a preceding MS attack and Neurological abnormality lasting for at least 24 hours, absence of fever or known infection greater than 37.5 degree centigrade /99.5 degree fahrenheit , objective neurological impairment, correlating with the subject's reported symptoms, defined as either increase in at least one of the functional systems of the EDSS or increase of the total EDSS score and occurrence of paraesthesia, fatigue, mental symptoms, and/or vegetative symptoms without any additional symptom will not be classified as an MS attack.

    Time frame: 48 weeks

  14. Percentage of Subjects Treated With Glucocorticoids Due to Relapses

    Relapse was defined as neurological abnormality, either newly appearing or re-appearing, with abnormality specified by both as neurological abnormality separated by at least 30 days from onset of a preceding MS attack and Neurological abnormality lasting for at least 24 hours, absence of fever or known infection greater than 37.5 degree centigrade /99.5 degree fahrenheit , objective neurological impairment, correlating with the subject's reported symptoms, defined as either increase in at least one of the functional systems of the EDSS or increase of the total EDSS score and occurrence of paraesthesia, fatigue, mental symptoms, and/or vegetative symptoms without any additional symptom will not be classified as an MS attack.

    Time frame: Baseline upto 48 weeks

  15. Mean Change From Baseline in the Total Volume of T1 Hypo Intense Lesions at Week 48

    Time frame: Baseline, 48 Weeks

07

Results

Posted Jul 11, 2016

Participant flow

Participant flow — Overall Study
MilestoneVigantOL Oil Interferon Beta-1a (Rebif)Placebo Interferon Beta-1a (Rebif)
Started115117
Treated113116
Completed9888
Not completed1729
Withdrew: Prematurely withdrawn from the study1729

Outcome measures

PrimaryPercentage of Subjects With Disease Activity Free Status up to Week 48

Disease activity free status was defined as absence of any of the clinical and imaging parameters related to the assessment of disease activity; no relapses, no expanded disability status scale (EDSS) progression and no new gadolinium (Gd)-enhancing or relaxation time 2 (T2) magnetic resonance imaging (MRI) lesions.

Time frame:
Up to Week 48
Reported as:
Number · percentage of subjects
Percentage of Subjects With Disease Activity Free Status up to Week 48
percentage of subjectsVigantOL Oil Interferon Beta-1a (Rebif)Placebo Interferon Beta-1a (Rebif)
Percentage of Subjects With Disease Activity Free Status up to Week 4837.235.3
SecondaryPercentage of Relapse-free Subjects at Week 48

A relapse was defined as the development of new or the exacerbation of existing neurological symptoms or signs, in the absence of fever, lasting for 24 hours and with a previous period for more than 30 days with a stable or an improving condition.

Time frame:
Week 48
Reported as:
Number · percentage of subjects
Percentage of Relapse-free Subjects at Week 48
percentage of subjectsVigantOL Oil Interferon Beta-1a (Rebif)Placebo Interferon Beta-1a (Rebif)
Percentage of Relapse-free Subjects at Week 4878.875.0
SecondaryPercentage of Subjects Free From Any Expanded Disability Status Scale (EDSS) Progression at Week 48

EDSS assesses disability in 8 functional systems. An overall score ranging from 0 (normal) to 10 (death due to MS) was calculated. A confirmed EDSS progression was defined EDSS greater than or equal to 1.0 point confirmed during a visit performed 6 months later. An EDSS progression was defined as an increase of the EDSS score of at least 1.0 point compared to baseline (SD1) for subjects with a baseline EDSS ≤ 4.0. For subjects with an EDSS score of 0 at baseline (SD1), EDSS progression was defined as an increase of at least 1.5 points. A confirmed EDSS progression was defined as an EDSS progression confirmed after 24 weeks.

Time frame:
Week 48
Reported as:
Number · percentage of subjects
Percentage of Subjects Free From Any Expanded Disability Status Scale (EDSS) Progression at Week 48
percentage of subjectsVigantOL Oil Interferon Beta-1a (Rebif)Placebo Interferon Beta-1a (Rebif)
Percentage of Subjects Free From Any Expanded Disability Status Scale (EDSS) Progression at Week 4871.775.0
SecondaryNumber od Subjects With Confirmed EDSS Progression

EDSS assesses disability in 8 functional systems. An overall score ranging from 0 (normal) to 10 (death due to MS) was calculated. A confirmed EDSS progression was defined EDSS greater than or equal to 1.0 point confirmed during a visit performed 6 months later. An EDSS progression was defined as an increase of the EDSS score of at least 1.0 point compared to baseline (SD1) for subjects with a baseline EDSS ≤ 4.0. For subjects with an EDSS score of 0 at baseline (SD1), EDSS progression was defined as an increase of at least 1.5 points. A confirmed EDSS progression was defined as an EDSS progression confirmed after 24 weeks.

Time frame:
Baseline upto 48 Weeks
Reported as:
Number · subjects
Number od Subjects With Confirmed EDSS Progression
subjectsVigantOL Oil Interferon Beta-1a (Rebif)Placebo Interferon Beta-1a (Rebif)
Number od Subjects With Confirmed EDSS Progression84
SecondaryCumulative Number of Relaxation Time 1 (T1) Gadolinium Enhancing Lesions at Week 48
Time frame:
48 Weeks
Reported as:
Mean · lesions per subject per scan
Cumulative Number of Relaxation Time 1 (T1) Gadolinium Enhancing Lesions at Week 48
lesions per subject per scanVigantOL Oil Interferon Beta-1a (Rebif)Placebo Interferon Beta-1a (Rebif)
Cumulative Number of Relaxation Time 1 (T1) Gadolinium Enhancing Lesions at Week 480.36 ± 1.730.25 ± 0.67
SecondaryMean Number of Combined Unique Active (CUA) Lesions Per Subject Per Scan at Week 48

CUA lesions was defined as new T1 (Gd enhancing) lesions, new Relaxation time 2 (T2) lesions, or enlarging T2 lesions.

Time frame:
48 Weeks
Reported as:
Mean · lesions per subject per scan
Mean Number of Combined Unique Active (CUA) Lesions Per Subject Per Scan at Week 48
lesions per subject per scanVigantOL Oil Interferon Beta-1a (Rebif)Placebo Interferon Beta-1a (Rebif)
Mean Number of Combined Unique Active (CUA) Lesions Per Subject Per Scan at Week 481.09 ± 3.841.49 ± 4.31
SecondaryCumulative Number of New Combined Unique Active (CUA) Lesions at Week 48

CUA lesions was defined as new T1 (Gd enhancing) lesions, new T2 lesions, or enlarging T2 lesions.

Time frame:
48 Weeks
Reported as:
Mean · lesions per subject per scan
Cumulative Number of New Combined Unique Active (CUA) Lesions at Week 48
lesions per subject per scanVigantOL Oil Interferon Beta-1a (Rebif)Placebo Interferon Beta-1a (Rebif)
Cumulative Number of New Combined Unique Active (CUA) Lesions at Week 481.09 ± 3.841.49 ± 4.31
SecondaryMean Change From Baseline in the Total Volume of T2 Lesions at Week 48 (T2 Burden of Disease)
Time frame:
Baseline, 48 Weeks
Reported as:
Mean · millimeter^3 (mm^3)
Mean Change From Baseline in the Total Volume of T2 Lesions at Week 48 (T2 Burden of Disease)
millimeter^3 (mm^3)VigantOL Oil Interferon Beta-1a (Rebif)Placebo Interferon Beta-1a (Rebif)
Mean Change From Baseline in the Total Volume of T2 Lesions at Week 48 (T2 Burden of Disease)130.38 ± 830.8295.75 ± 401.87
SecondaryPercentage of Subjects Free From T1 Gadolinium Enhancing Lesions at Week 48
Time frame:
48 Weeks
Reported as:
Number · percentage of subjects
Percentage of Subjects Free From T1 Gadolinium Enhancing Lesions at Week 48
percentage of subjectsVigantOL Oil Interferon Beta-1a (Rebif)Placebo Interferon Beta-1a (Rebif)
Percentage of Subjects Free From T1 Gadolinium Enhancing Lesions at Week 4883.270.7
SecondaryPercentage of Subjects Free From New T1 Hypointense Lesions (Black Holes) at Week 48
Time frame:
48 Weeks
Reported as:
Number · percentage of subjects
Percentage of Subjects Free From New T1 Hypointense Lesions (Black Holes) at Week 48
percentage of subjectsVigantOL Oil Interferon Beta-1a (Rebif)Placebo Interferon Beta-1a (Rebif)
Percentage of Subjects Free From New T1 Hypointense Lesions (Black Holes) at Week 4878.863.8
SecondaryPercentage of New T1 Hypointense Lesions (Black Holes) at Week 48 Within the Subgroup of New or Enlarging Non-enhancing T2 Lesions
Time frame:
48 Weeks
Reported as:
Mean · percentage of new T1 hypointense lesions
Percentage of New T1 Hypointense Lesions (Black Holes) at Week 48 Within the Subgroup of New or Enlarging Non-enhancing T2 Lesions
percentage of new T1 hypointense lesionsVigantOL Oil Interferon Beta-1a (Rebif)Placebo Interferon Beta-1a (Rebif)
Percentage of New T1 Hypointense Lesions (Black Holes) at Week 48 Within the Subgroup of New or Enlarging Non-enhancing T2 Lesions20.11 ± 34.7227.70 ± 39.33
SecondaryNumber of Subjects With Relapse

Relapse was defined as neurological abnormality, either newly appearing or re-appearing, with abnormality specified by both as neurological abnormality separated by at least 30 days from onset of a preceding MS attack and Neurological abnormality lasting for at least 24 hours, absence of fever or known infection greater than 37.5 degree centigrade /99.5 degree fahrenheit , objective neurological impairment, correlating with the subject's reported symptoms, defined as either increase in at least one of the functional systems of the EDSS or increase of the total EDSS score and occurrence of paraesthesia, fatigue, mental symptoms, and/or vegetative symptoms without any additional symptom will not be classified as an MS attack.

Time frame:
Baseline upto 48 weeks
Reported as:
Number · subjects
Number of Subjects With Relapse
subjectsVigantOL Oil Interferon Beta-1a (Rebif)Placebo Interferon Beta-1a (Rebif)
Number of Subjects With Relapse2429
SecondaryAnnualized Relapse Rate at Week 48

Relapse was defined as neurological abnormality, either newly appearing or re-appearing, with abnormality specified by both as neurological abnormality separated by at least 30 days from onset of a preceding MS attack and Neurological abnormality lasting for at least 24 hours, absence of fever or known infection greater than 37.5 degree centigrade /99.5 degree fahrenheit , objective neurological impairment, correlating with the subject's reported symptoms, defined as either increase in at least one of the functional systems of the EDSS or increase of the total EDSS score and occurrence of paraesthesia, fatigue, mental symptoms, and/or vegetative symptoms without any additional symptom will not be classified as an MS attack.

Time frame:
48 weeks
Reported as:
Mean · relapse per year
Annualized Relapse Rate at Week 48
relapse per yearVigantOL Oil Interferon Beta-1a (Rebif)Placebo Interferon Beta-1a (Rebif)
Annualized Relapse Rate at Week 480.28 ± 0.590.41 ± 0.83
SecondaryTotal Number of Reported Relapses at All Time Points up to 48 Weeks

Relapse was defined as neurological abnormality, either newly appearing or re-appearing, with abnormality specified by both as neurological abnormality separated by at least 30 days from onset of a preceding MS attack and Neurological abnormality lasting for at least 24 hours, absence of fever or known infection greater than 37.5 degree centigrade /99.5 degree fahrenheit , objective neurological impairment, correlating with the subject's reported symptoms, defined as either increase in at least one of the functional systems of the EDSS or increase of the total EDSS score and occurrence of paraesthesia, fatigue, mental symptoms, and/or vegetative symptoms without any additional symptom will not be classified as an MS attack.

Time frame:
48 weeks
Reported as:
Mean · number of relapse per subject
Total Number of Reported Relapses at All Time Points up to 48 Weeks
number of relapse per subjectVigantOL Oil Interferon Beta-1a (Rebif)Placebo Interferon Beta-1a (Rebif)
Total Number of Reported Relapses at All Time Points up to 48 Weeks0.25 ± 0.530.34 ± 0.63
SecondaryPercentage of Subjects Treated With Glucocorticoids Due to Relapses

Relapse was defined as neurological abnormality, either newly appearing or re-appearing, with abnormality specified by both as neurological abnormality separated by at least 30 days from onset of a preceding MS attack and Neurological abnormality lasting for at least 24 hours, absence of fever or known infection greater than 37.5 degree centigrade /99.5 degree fahrenheit , objective neurological impairment, correlating with the subject's reported symptoms, defined as either increase in at least one of the functional systems of the EDSS or increase of the total EDSS score and occurrence of paraesthesia, fatigue, mental symptoms, and/or vegetative symptoms without any additional symptom will not be classified as an MS attack.

Time frame:
Baseline upto 48 weeks
Reported as:
Number · percentage of subjects
Percentage of Subjects Treated With Glucocorticoids Due to Relapses
percentage of subjectsVigantOL Oil Interferon Beta-1a (Rebif)Placebo Interferon Beta-1a (Rebif)
Percentage of Subjects Treated With Glucocorticoids Due to Relapses15.920.7
SecondaryMean Change From Baseline in the Total Volume of T1 Hypo Intense Lesions at Week 48
Time frame:
Baseline, 48 Weeks
Reported as:
Mean · millimeter^3 (mm^3)
Mean Change From Baseline in the Total Volume of T1 Hypo Intense Lesions at Week 48
millimeter^3 (mm^3)VigantOL Oil Interferon Beta-1a (Rebif)Placebo Interferon Beta-1a (Rebif)
Mean Change From Baseline in the Total Volume of T1 Hypo Intense Lesions at Week 4820.88 ± 140.5618.47 ± 68.08
Post-hocPercentage of Subjects With Disease Activity Free Status (Alternate Definition) at Week 48

Disease activity free (DAF) status was defined as absence of any of the clinical and imaging parameters related to the assessment of disease activity; no relapses, no confirmed expanded disability status scale (EDSS) progression and no new gadolinium (Gd)-enhancing or relaxation time 2 (T2) magnetic resonance imaging (MRI) lesions. Confirmed EDSS progression was defined as an EDSS progression confirmed after 24 weeks.

Time frame:
Week 48
Reported as:
Number · percentage of subjects
Percentage of Subjects With Disease Activity Free Status (Alternate Definition) at Week 48
percentage of subjectsVigantOL Oil Interferon Beta-1a (Rebif)Placebo Interferon Beta-1a (Rebif)
Percentage of Subjects With Disease Activity Free Status (Alternate Definition) at Week 4847.837.9

Adverse events

Collected over Baseline up to end of trial (EOT: 50 months). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
VigantOL Oil Interferon Beta-1a (Rebif)—18/113 (15.9%)99/113 (87.6%)
Placebo Interferon Beta-1a (Rebif)—8/116 (6.9%)93/116 (80.2%)
Most frequent serious events
Showing 10 of 18
Most frequent serious events
EventVigantOL Oil Interferon Beta-1a (Rebif)Placebo Interferon Beta-1a (Rebif)
OverdoseInjury, poisoning and procedural complications8/1136/116
Abscess limbInfections and infestations1/1130/116
AppendicitisInfections and infestations1/1130/116
CellulitisInfections and infestations1/1130/116
PneumoniaInfections and infestations1/1130/116
PyelonephritisInfections and infestations1/1130/116
Breast cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/1130/116
Ovarian cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/1130/116
DepressionPsychiatric disorders1/1130/116
SyncopeNervous system disorders1/1130/116
Most frequent other events
Showing 10 of 307
Most frequent other events
EventVigantOL Oil Interferon Beta-1a (Rebif)Placebo Interferon Beta-1a (Rebif)
HeadacheNervous system disorders20/11321/116
InfluenzaInfections and infestations13/11319/116
NasopharyngitisInfections and infestations18/11317/116
Pain in extremityMusculoskeletal and connective tissue disorders13/1136/116
FatigueGeneral disorders8/11313/116
Influenza like illnessGeneral disorders12/11313/116
Urinary tract infectionInfections and infestations12/1136/116
PyrexiaGeneral disorders7/11312/116
DiarrhoeaGastrointestinal disorders10/1137/116
Back painMusculoskeletal and connective tissue disorders10/1137/116

Baseline characteristics

Baseline analysis set included all randomized subjects.

Age, Continuous
Age, Continuous(years)VigantOL Oil Interferon Beta-1a (Rebif)Placebo Interferon Beta-1a (Rebif)Total
Mean34.2 ± 8.133.6 ± 9.333.9 ± 8.8
Sex: Female, Male
Sex: Female, Male(Participants)VigantOL Oil Interferon Beta-1a (Rebif)Placebo Interferon Beta-1a (Rebif)Total
Female7879157
Male373875
08

Study locations

38 sites
  • Research Site
    Vienna, Austria
  • Research Site
    Esbjerg, Denmark
  • Research Site
    Glostrup, Denmark
  • Research Site
    Sønderborg, Denmark
  • Research Site
    Vejle, Denmark
  • Research Site
    Viborg, Denmark
  • Research Site
    Tallinn, Estonia
  • Research Site
    Helsinki, Finland
  • Research Site
    Turku, Finland
  • Research Site
    Bad Neustadt / Saale, Germany
  • Research Site
    Bamberg, Germany
  • Research Site
    Berlin, Germany
  • Research Site
    Erlangen, Germany
  • Research Site
    Freiburg, Germany
  • Research Site
    Hannover, Germany
  • Research Site
    Köln, Germany
  • Research Site
    Münster, Germany
  • Research Site
    Regensburg, Germany
  • Research Site
    Rostock, Germany
  • Research Site
    Cefalu, Italy
  • Research Site
    Riga, Latvia
  • Research Site
    Kaunas, Lithuania
  • Research Site
    Amsterdam, Netherlands
  • Research Site
    Gouda, Netherlands
  • Research Site
    Nieuwegein, Netherlands
  • Research Site
    Rotterdam, Netherlands
  • Research Site
    Sittard, Netherlands
  • Research Site
    Bergen, Norway
  • Research Site
    Lørenskog, Norway
  • Research Site
    Tromsø, Norway
  • Research Site
    Amadora, Portugal
  • Research Site
    Lisboa, Portugal
  • Research Site
    Porto, Portugal
  • Research Site
    Bern, Switzerland
  • Research Site
    Lausanne, Switzerland
  • Research Site
    Lugano, Switzerland
  • Research Site
    St. Gallen, Switzerland
  • Research Site
    Zurich, Switzerland
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2011, a primary completion of Apr 2015 and a completion of May 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Jul 2016, 1 year 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 26, 2011
First posted
Jan 28, 2011
Start
Feb 2011
Primary completionActual
Apr 2015
CompletionActual
May 2015
Results first posted
Jul 11, 2016
Last update
Nov 28, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 28, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01285401
Responsible party
Sponsor
First posted
Jan 28, 2011
Start date
Feb 2011
Primary completion
Apr 2015
Completion
May 2015
Results posted
Jul 11, 2016
Last update
Nov 28, 2016

Study contacts

Manolo Beelke, MD, PhD
study director · WCT Worldwide Clinical Trials GER GmbH Germany
Prof. Dr. Raymond Hupperts, MD
principal investigator · Dept of Neurology, Orbis Medical Center Sittard, Maastricht University, The Netherlands

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Interferon beta-1a

Start the discussion